At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 12 enrolled
Drug / intervention
Tadalafildrug
Likely dose
Tadalafil 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tadalafil for Sarcoidosis Associated Pulmonary Hypertension
In Brief
A Phase 3 clinical trial evaluating Tadalafil for Pulmonary Hypertension. Completed, enrolled 12 participants across 2 sites.
Detailed Summary
This study is designed to assess safety and efficacy of tadalafil in patients with Sarcoidosis Associated Pulmonary Hypertension. Hypothesis: Tadalafil is safe and effective in treating pulmonary hypertension in patients with Sarcoidosis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Hypertension
CountriesUnited States
CollaboratorsEli Lilly and Company, United Therapeutics, University of Cincinnati
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedMar 2011
Primary CompletionJul 2013
Study CompletionOct 2013
TodayJul 2026
First PostedMar 29, 2011
Enrollment StartMar 1, 2011
Primary CompletionJul 1, 2013
Study CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.3 years ago
Interventions
Tadalafildrug
20mg/day for one month then 40mg/day for additional 4 months